Activase (alteplase) - Roche, Boehringer Ingelheim, Kyowa Kirin, Tanabe Pharma
Intravenous alteplase compared with standard medical treatment for stroke aged over 70 years: a secondary analysis of the HOPE randomised clinical trial. (PubMed, Stroke Vasc Neurol) - Sep 17, 2026 - "This secondary analysis suggests that the evidence trends towards safety and effectiveness of intravenous alteplase in patients aged over 70 years during 4.5 to 24 hours after stroke onset." 
Journal • Cardiovascular • Cerebral Hemorrhage • Ischemic stroke
http://www.ncbi.nlm.nih.gov/pubmed/42749350
 
Changcai Meng; Hezhong Ouyang; Jianhua Cheng; Min Lou; Shenqiang Yan; Tingyu Yi; Yanxing Zhang; Yaode He; Ying Zhou; Zuowen Zhang
 
Sep 17, 2026
 
Prev Next